Howard University Telehealth Training Center
HUTTC Home | About | News | Current Projects | Past Projects | On-Demand Videos and Podcasts

4. Issues of Ethnopharmacology in HIV Management

Agents Targeting Different HIV Tropisms

Maraviroc

Maraviroc (Selzentry®) is the only CCR5 antagonist that has received FDA approval for marketing and is licensed for the treatment of CCR5-tropic HIV-1 in both treatment-experienced and treatment-naive adults—in combination with other antiretrovirals in both populations. Maraviroc is available in tablet form, with a recommended dose of 300 mg twice daily for most patients to be taken with or without food. The most common adverse events observed in studies clinical trials include cough, fever, dizziness, headache, lowered blood pressure, nausea, and bladder irritation. Possible liver problems and cardiac events, increased risk for some infections, and a slight increase in cholesterol levels have also been reported. Drug interactions with maraviroc have been observed when it is coadministered with certain other antiretrovirals, including efavirenz and lopinavir/ritonavir. The resulting changes in maraviroc exposure levels require use of different doses of maraviroc.

Vicriviroc

Further development of the CCR5 antagonist vicriviroc was discontinued in 2010 due to lack of evidence in clinical trials that use of the drug significantly improved clinical outcomes in either treatment-experienced or treatment-naive patients.

Cenicriviroc

Cenicriviroc is an orally available CCR5 antagonist that is currently in phase 2 trials in antiretroviral-naive patients.

AMD11070

AMD11070 is an orally available CXCR4 antagonist that has completed early-phase development in both antiretroviral-experienced and antiretroviral-naive patients.

« BACK

NEXT »